ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Benefit of Latanoprostene Bunod (Vyzulta) for Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Cohort Study in Taiwan.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo compare the reduction in intraocular pressure (IOP) over 12 months after switching from latanoprost to latanoprostene bunod (LBN) in different glaucoma subtypes, including primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PXFG), and neovascular glaucoma (NVG), and to assess the clinical significance of any differential IOP response.
methodsWe conducted a retrospective chart review of 103 patients with POAG (n = 42), PXFG (n = 30), or NVG (n = 31) who were treated with latanoprost 0.005% and switched to LBN monotherapy (0.024%). All other ocular hypotension treatments remained unchanged. The IOP was recorded at baseline and 1, 3, 6, and 12 months after switching. Repeated-measures ANOVA was used to assess the longitudinal IOP changes within groups, and between-group differences were evaluated using one-way ANOVA, followed by post-hoc testing.
resultsThe baseline IOP was significantly higher in the NVG group compared to the POAG group. At 12 months, the mean IOP reductions were - 9.9% in POAG (p < 0.001 vs. baseline), - 16.7% in PXFG (p < 0.001), and - 1.4% in NVG (p = 0.63). PXFG eyes experienced significantly greater IOP lowering than POAG (p = 0.033) and NVG (p < 0.001), while the NVG eyes derived no meaningful benefit.
conclusionsLBN demonstrated differential IOP-lowering effects across glaucoma subtypes, with a notably enhanced effect on PXFG. This superior efficacy in PXFG, likely due to LBN's dual mechanism overcoming pseudoexfoliative outflow resistance, suggests that switching from latanoprost may help delay the need for surgical intervention in this challenging patient population.
Indexed as
Identifiers
41420784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.